Join Emergent in recognizing NALOXONE AWARENESS DAY on June 6

Emergent is proud to be the producer of NARCAN® Nasal Spray. NARCAN® Nasal Spray is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose.

LEARN MORE

Opioid emergencies can happen anywhere, any time

As part of Emergent’s advocacy work around the opioid epidemic, we have partnered with Emmitt Smith to launch Ready to Rescue Campaign to help save lives amidst the rising opioid epidemic.

LEARN MORE

About Naloxone and Opioid Overdose

  • What is naloxone?

    Naloxone is an emergency medication designed to immediately help reverse an opioid overdose. It can restore breathing after it has slowed or stopped.

    Source: NIDA

  • How does naloxone work? 

    Naloxone competes with opioids to bind with the same receptors in the brain, reversing the effects of an opioid overdose in minutes. This allows time for emergency medical help to arrive. Be sure to use as directed and always call 911 immediately after giving the first dose of naloxone.

    Source: NIDA

  • What are the signs and symptoms of an opioid overdose?

    Signs of an opioid overdose may include:

    • Unconsciousness or unable to wake up
    • Slow or shallow breathing or difficulty breathing
    • Discolored skin, nails, or lips
    • Small, constricted “pinpoint pupils” that don’t react to light

    Source: CDC

At Emergent, we’re committed to doing our part to reduce opioid overdose deaths.

Learn More

Emergent BioSolutions Reports First Quarter 2024 Financial Results

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024.
Read More

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced the next phase of its new operational plan that consolidates operations, closes several manufacturing facilities, and restructures its enterprise workforce to improve the performance and profitability of its business. Emergent will continue to focus on its core products business – medical countermeasures and NARCAN® Nasal Spray –and on delivering for its patients and customers, including the U.S. and allied governments.
Read More

Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone

GAITHERSBURG, Md., May 01, 2024 -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new national public opinion survey showing that more than 90 percent of Americans surveyed recognize opioid overdoses are a pressing concern for teenagers and college students, and more than 9 in 10 parents in the survey agree schools should do more to educate on the risks of opioids and how to respond to an overdose.
Read More
READ ALL NEWS

This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.